Immune to Cancer: The CRI Blog
-
Cancer Research Institute Wins $1 Million from Revlon for Women’s Cancers
We took first place in the second annual Revlon LOVE IS ON Million Dollar Challenge.
-
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
First-line lung cancer immunotherapy approval results from century-long effort to harness the immune system to fight cancer.
-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
CICON16: The Future of Cancer Immunotherapy
CICON16 ended by focusing on emerging treatments and technologies in cancer immunotherapy.
-
CICON16: The Power of Combinations
Targeting tumors from multiple angles improves our odds of success.
-
CICON16: Bacteria and Cancer Immunity
New research shows that bacteria within us can influence both the development of cancer and the immune…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.